Literature DB >> 29046878

Determination of the Proteomic Response to Lapatinib Treatment using a comprehensive and reproducible ion-current-based proteomics strategy.

Kathleen O'Connell1, Jun Li2, Frank Engler2, Kim Hennessy3, Fiona O'Neill4, Robert M Straubinger2, Jun Qu2, Robert O'Connor4,5.   

Abstract

Lapatinib, a small molecule tyrosine kinase inhibitor is currently used in the treatment of HER2-positive breast cancer. The aim of this study was to further understanding of lapatinib response for the development of novel treatment lapatinib-focussed treatment strategies. HER2-overexpressing SKBR3 breast cancer cells were treated with lapatinib for 12 hours and the resultant proteome analyzed by a comprehensive ion-current-based LC-MS strategy. Among the 1224 unique protein identified from SKBR3 cell lysates, 67 showed a significant change in protein abundance in response to lapatinib. Of these, CENPE a centromeric protein with increased abundance, was chosen for further validation. Knockdown and inhibition of CENPE demonstrated that CENPE enhances SKBR3 cell survival in the presence of lapatinib. Based on this study, CENPE inhibitors may warrant further investigation for use in combination with lapatinib.

Entities:  

Keywords:  Breast; CENPE; Cancer; HER2; LC-MS; lapatinib

Year:  2013        PMID： 29046878      PMCID： PMC5642974          DOI： 10.14302/issn.2326-0793.jpgr-13-257

Source DB:  PubMed          Journal:  J Proteom Genom Res        ISSN： 2326-0793


  32 in total

1.  CENP-E as an essential component of the mitotic checkpoint in vitro.

Authors:  A Abrieu; J A Kahana; K W Wood; D W Cleveland
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

2.  Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

Authors:  Neil A O'Brien; Brigid C Browne; Lucy Chow; Yuhua Wang; Charles Ginther; Jane Arboleda; Michael J Duffy; John Crown; Norma O'Donovan; Dennis J Slamon
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

3.  Utility of cleavable isotope-coded affinity-tagged reagents for quantification of low-copy proteins induced by methylprednisolone using liquid chromatography/tandem mass spectrometry.

Authors:  Jun Qu; William J Jusko; Robert M Straubinger
Journal:  Anal Chem       Date:  2006-07-01       Impact factor: 6.986

4.  Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.

Authors:  Richard B Lock; Hernan Carol; Christopher L Morton; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Amy W Wozniak; Richard Gorlick; E Anders Kolb; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2011-05-16       Impact factor: 3.167

5.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

Authors:  D W Rusnak; K Affleck; S G Cockerill; C Stubberfield; R Harris; M Page; K J Smith; S B Guntrip; M C Carter; R J Shaw; A Jowett; J Stables; P Topley; E R Wood; P S Brignola; S H Kadwell; B R Reep; R J Mullin; K J Alligood; B R Keith; R M Crosby; D M Murray; W B Knight; T M Gilmer; K Lackey
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

6.  Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer.

Authors:  Ming Lu; Stephen A Whelan; Jianbo He; Romaine E Saxton; Kym F Faull; Julian P Whitelegge; Helena R Chang
Journal:  Clin Proteomics       Date:  2010-09-07       Impact factor: 3.988

7.  Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay.

Authors:  Marcel Tanudji; John Shoemaker; Lawrence L'Italien; Loren Russell; Gregory Chin; Xiao Min Schebye
Journal:  Mol Biol Cell       Date:  2004-06-04       Impact factor: 4.138

8.  Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.

Authors:  Priti S Hegde; David Rusnak; Melissa Bertiaux; Krystal Alligood; Jay Strum; Robert Gagnon; Tona M Gilmer
Journal:  Mol Cancer Ther       Date:  2007-05       Impact factor: 6.261

9.  Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.

Authors:  Fiona O'Neill; Stephen F Madden; Sinead T Aherne; Martin Clynes; John Crown; Padraig Doolan; Robert O'Connor
Journal:  Mol Cancer       Date:  2012-06-18       Impact factor: 27.401

10.  Cyclin-like accumulation and loss of the putative kinetochore motor CENP-E results from coupling continuous synthesis with specific degradation at the end of mitosis.

Authors:  K D Brown; R M Coulson; T J Yen; D W Cleveland
Journal:  J Cell Biol       Date:  1994-06       Impact factor: 10.539
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.